



Convening leading members of Illinois' oncology community to discuss precision medicine and identify possible policy solutions to four key barriers to improve patient outcomes.



PARTICIPANTS: COMMUNITY THOUGHT LEADERS

16 attendees, including multiple cancer advocacy organizations, oncologists, legislators, researchers, patient advocates, biotechnology experts and science officers and done in partnership with The American Cancer Society of Illinois.



CLINICAL

BARRIER: Precision medicines are quickly being approved, challenging health professionals and patients to stay abreast of new treatments and testing requirements to improve treatment decisions.

POLICY SOLUTION:

- › Set standards for continuing medical education
- › Promote next generation sequencing, and test as much up front to identify hereditary risks
- › Improve health education quality and access for at-risk populations
- › Allocate greater resources and attention to the needs of patients in rural areas via genetic counselors and patient navigators
- › Address a general shortage of patient navigators and genetic counselors



INFRASTRUCTURE

BARRIER: Legacy informatics systems used by most hospitals may have challenges managing the breadth and complexity of patient data, sometimes challenging clinicians to incorporate them into clinical practice.

POLICY SOLUTION:

- › Allow pathway for certain patient data to be shared with private research institutions while aligned with federal privacy protections to best support treatment
- › Increase access to telemedicine and translation services to support non-English speaking patients
- › Increase funding and reimbursement for patient navigators to serve as conduit at point of care to support infrastructure changes
- › Identify ways to streamline resources to ensure treatment facilities are providing comprehensive care at a single location



HCP COLLABORATION

BARRIER: Key decisions regarding sequencing often don't involve the entire treatment team. Not involving the entire treatment team can hinder uptake of novel technologies.

POLICY SOLUTION:

- › Ensure pathologists are working more closely with HCPs to ensure the right tests are ordered via comprehensive treatment boards
- › Establish registries to collect and analyze data to identify trends in precision medicine treatment
- › Give HCPs access to real-time and historical results to avoid repeat biopsies, costs and delays
- › Promote access to greater networks of labs where testing can occur
- › Encourage a greater reliance on external labs as opposed to overburdening hospital systems



REIMBURSEMENT

BARRIER: High standards for demonstrating clinical and economic utility pose coverage challenges for novel diagnostics and implementing consistent coverage and payment for testing.

POLICY SOLUTION:

- › Eliminate lifetime and annual limits on testing and streamline reimbursement for full multiple gene testing and remove lifetime limits
- › Educate payors on the economic value of paying for tests and screens and clinician-recommended treatments
- › Streamline process and regulatory burden for prescribing clinician-recommended treatments
- › Streamline reimbursement for full multiple gene testing and remove lifetime limits on testing

A LOOK
AHEAD

Foster
conversation
among attendees

Collaborate with
Legislators

Build support
with medical
oncology

Identify
ways to support
policy efforts

Precision Medicine Roundtables are a part of AstraZeneca's YOUR Cancer initiative, which convenes the oncology community to eliminate cancer as a cause of death.

Learn more at www.YourCancer.org.